Efficacy of Magnesium Sulfate Treatment in Children with Acute Asthma.

---

Atıf İçin Kopyala

Özdemir A., Doğruel D.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre, cilt.29, ss.292-298, 2020 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 29
• Basım Tarihi: 2020
• Doi Numarası: 10.1159/000506595
• Dergi Adı: Medical principles and practice : international journal of the Kuwait University, Health Science Centre
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
• Sayfa Sayıları: ss.292-298
• Anahtar Kelimeler: Magnesium sulfate, Spirometry, Asthma, Children, PEDIATRIC ASTHMA, PLACEBO, MODERATE, THERAPY
• Çukurova Üniversitesi Adresli: Evet

Özet

Objective: Systemic administration of magnesium sulfate (MgSO₄) has been proposed as a treatment for pediatric patients with acute asthma. However, previous trials show mixed results and uncertain evidence of benefit. The aim of the study was to ascertain whether intravenous (IV) MgSO₄ improves lung function parameters in children with acute asthma. Methods: This was a prospective clinical trial. All patients with acute asthma received 40-50 mg/kg or maximum 1,500 mg (>30 kg) of single dose IV MgSO₄, administered over 60 min. Spirometry was conducted before and 15 min after MgSO₄ infusion. Results: One hundred and fifteen children aged 6 to 17 years presenting with acute asthma and FEV₁ between 40% and 75% of predicted were included. Then, the patients were classified into 2 groups; mild asthma attack (FEV₁ ranged from 60% to 75%; n = 50) or moderate asthma attack (FEV₁ ranged from 40% to 59%; n = 65). The baseline characteristics were similar in both groups. The mean percent predicted pre and post values for FEV₁/FVC ratio (mild group: 82.59 +/- 9.46 vs. 85.06 +/- 8.95; moderate group: 77.31 +/- 11.17 vs. 79.99 +/- 11.77), FEV₁ (mild group: 67.14 +/- 4.99 vs. 72.29 +/- 8.05; moderate group: 48.50 +/- 6.81 vs. 53.78 +/- 9.81), PEF (mild group: 65.49 +/- 12.32 vs. 71.37 +/- 12.96; moderate group: 47.56 +/- 11.78 vs. 51.97 +/- 13.98), and FEF_25-75 (mild group: 58.20 +/- 12.24 vs. 66.57 +/- 16.95; moderate group: 37.77 +/- 11.37 vs. 43.41 +/- 14.19) showed a statistically significant (p < 0.05 for all) bronchodilator effect after MgSO₄ infusion in both groups with few side effects. Conclusion: Administration of IV MgSO₄ was associated with improved pulmonary function in children with acute asthma.